Results 1 to 10 of about 28,830 (241)
Efavirenz: History, Development and Future [PDF]
Biomolecules, 2022 Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the spread of HIV.
Bárbara Costa, Nuno Vale
doaj +3 more sources
Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study [PDF]
Clinical and Translational ScienceCoproporphyrin I (CPI) is increasingly recognized as a reliable endogenous biomarker for hepatic OATP1B transporters. However, confounding mechanisms such as increased heme biosynthesis driven by induction of CYP enzymes, which are hemoproteins, may ...
Leila Potzel +5 more
doaj +3 more sources
Expert Opinion on Pharmacotherapy, 2007 Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection.
Ferdinand Wnm Wit
exaly +4 more sources
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. [PDF]
PLoS ONE, 2013 We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations.ART naïve HIV patients from Ethiopia (n = 285) and Tanzania (n = 209 ...
Eliford Ngaimisi +13 more
doaj +3 more sources
Reactions Weekly, 2017 rapid, specific and accurate isocratic HPLC method was developed and validated for the assay of efavirenz in pharmaceutical dosage forms. The assay involved an isocratic elution of efavirenz in Grace C18 column using mobile phase composition of buffer ...
kiran B (7000028)
core +5 more sources
Influence of milling process on efavirenz solubility
Journal of Pharmacy and Bioallied Sciences, 2017 Introduction: The aim of this study was to investigate the influence of the milling process on the solubility of efavirenz. Materials and Methods: Milling process was done using Nanomilling for 30, 60, and 180 min.
Erizal Zaini +3 more
doaj +2 more sources
Interaction and compatibility studies of efavirenz with pharmaceutical excipients [PDF]
Journal of Excipients and Food Chemicals, 2016 Although excipients have traditionally been thought of as being inert, experience has shown that there can be interactions between excipients and drugs. Thus, knowledge of potential physical and chemical interactions can be very useful. The compatibility
Cinira Fandaruff +7 more
doaj +1 more source
Induction of Multiple Drug Transporters by Efavirenz
Journal of Pharmacological Sciences, 2009 Efavirenz, an important component of human immunodeficiency virus 1 (HIV-1) therapy, causes substantial drug interactions as an inducer of cytochromes and the transporter ABCB1. So far its effect on the expression of other transporters is unknown.
Johanna Weiss +5 more
doaj +2 more sources
A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe [PDF]
CPT: Pharmacometrics & Systems PharmacologyEfavirenz induces and inhibits multiple drug‐metabolizing enzymes, contributing to significant drug–drug interactions. This study quantified the impact of multiple doses of efavirenz on CYP3A activity via midazolam metabolism using a population ...
Kimberly S. Collins +6 more
doaj +2 more sources
Infection and Drug Resistance, 2023 Tongtong Wang,1,* Yingchu Liu,2,* Chunyu Zhu,1,* Siyuan Yang,3 Di Yang,4 Jiang Xiao,4 Guiju Gao4 1Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2School of General Practice and Continuing Education ...
Wang T +6 more
doaj +1 more source